# Rituximab and Combination Chemotherapy in Treating Older Patients With Diffuse Large B-Cell Lymphoma

> **NCT00101010** · PHASE2 · COMPLETED · sponsor: **M.D. Anderson Cancer Center** · enrollment: 80 (actual)

## Conditions studied

- Lymphoma

## Interventions

- **BIOLOGICAL:** Filgrastim
- **BIOLOGICAL:** Pegfilgrastim
- **BIOLOGICAL:** Rituximab
- **DRUG:** Cyclophosphamide
- **DRUG:** Pegylated liposomal doxorubicin hydrochloride
- **DRUG:** Prednisone
- **DRUG:** Vincristine Sulfate

## Key facts

- **NCT ID:** NCT00101010
- **Lead sponsor:** M.D. Anderson Cancer Center
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2005-09
- **Primary completion:** 2014-09
- **Final completion:** 2014-09
- **Target enrollment:** 80 (ACTUAL)
- **Last updated:** 2020-10-19

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00101010

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00101010, "Rituximab and Combination Chemotherapy in Treating Older Patients With Diffuse Large B-Cell Lymphoma". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT00101010. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*